Consensus Cipla Limited LUXEMBOURG S.E.

Stocks

CIPLA

US1729772095

Pharmaceuticals

End-of-day quote LUXEMBOURG S.E. 05/10/2026			5-day change	1st Jan Change
13.90 ^USD	-0.71%		-4.79%	-17.26%

09-22	Cipla Limited and Cipla Usa Inc. Announces Management Changes, Effective October 1, 2026	CI
09-03	India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar	RE

6646cc73af22b15012a700071e.-W7l6NXLN3n4fAJUb8FfeSz-bYU3xKRlyrL7pVFY6uk.qTidhZqnAQG2GzcgJKJuOgGaAcAFiP4krYuN72Uzu9iOPYOehLNBKZw1Sw~53e9f17c9cd4447d842005a32ffac7ee

Analysts' recommendations: Cipla Limited

07-24	Jefferies Adjusts Cipla's Price Target to INR1,170 From INR1,120, Keeps at Underperform	MT
06-24	Avendus Spark Upgrades Cipla to Buy from Add; Price Target is INR1,710	MT
05-14	Elara Securities Downgrades Cipla to Reduce from Accumulate; Price Target is INR1,349	MT
05-14	Elara Securities Downgrades Cipla to Sell from Neutral; Price Target is INR1,180	MT
05-14	JM Financial Upgrades Cipla to Buy from Add; Price Target is INR1,546	MT
05-14	Emkay Global Upgrades Cipla to Add from Reduce; Price Target is INR1,450	MT
05-14	Avendus Spark Upgrades Cipla to Add from Reduce; Price Target is INR1,455	MT
05-14	Nirmal Bang Downgrades Cipla to Hold from Buy; Price Target is INR1,404	MT
05-08	Jefferies Adjusts Cipla's Price Target to INR1,120 From INR1,170, Keeps at Underperform	MT
04-24	ICICI Securities Upgrades Cipla to Buy from Add; Price Target is INR1,550	MT
01-27	Nomura Adjusts Cipla's Price Target to INR1,510 From INR1,770, Keeps at Buy	MT
01-26	Jefferies Downgrades Cipla to Underperform From Hold, Adjusts Price Target to INR1,170 From INR1,630	MT
11-03	Nomura Adjusts Cipla's Price Target to INR1,770 From INR1,810, Keeps at Buy	MT
31/10/25	Choice Equity Downgrades Cipla to Add from Buy; Price Target is INR1,700	MT
31/10/25	Choice Equity Downgrades Cipla to Reduce from Add, Price Target is INR1,580	MT
31/10/25	Phillip Securities Upgrades Cipla to Neutral from Sell; Price Target is INR1,420	MT
31/10/25	Prabhudas Lilladher Downgrades Cipla to Accumulate from Buy, Price Target is INR1,675	MT
31/10/25	JM Financial Downgrades Cipla to Reduce from Hold; Price Target is INR1,600	MT
29/07/25	Nomura Adjusts Cipla's Price Target to INR1,810 From INR1,780, Keeps at Buy	MT
14/05/25	Jefferies Adjusts Cipla's Price Target to INR1,610 From INR1,580, Keeps at Hold	MT
31/01/25	Nomura Adjusts Cipla's Price Target to INR1,780 From INR1,800, Keeps at Buy	MT
29/01/25	Jefferies Adjusts Cipla's Price Target to INR1,580 From INR1,560, Keeps at Hold	MT
05/11/24	Nomura Upgrades Cipla to Buy From Neutral, Adjusts Price Target to INR1,800 From INR1,568	MT
30/10/24	Jefferies Adjusts Cipla's Price Target to INR1,480 From INR1,450, Keeps at Hold	MT
29/07/24	Jefferies Adjusts Cipla's Price Target to INR1,450 From INR1,400, Keeps at Hold	MT

More recommendations

Generic Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+16.27%
	JOHNSON & JOHNSON					+9.08%
	ABBVIE INC.					+6.1%
	MERCK & CO., INC.					+7.94%
	ROCHE HOLDING AG					+8.57%
	NOVARTIS AG					+8.14%
	ASTRAZENECA PLC					+34.02%
	AMGEN INC.					-3%
	GILEAD SCIENCES, INC.					+9.61%
	Average					+10.75%
	Weighted average by Cap.					+11.42%